Matthew Galsky
12
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
3 terminated/withdrawn out of 12 trials
70.0%
-16.5% vs industry average
0%
0 trials in Phase 3/4
114%
8 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Pembrolizumab in Muscle-invasive Bladder Cancer
Role: lead
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Role: lead
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Role: lead
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Role: lead
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Role: lead
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Role: lead
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Role: lead
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
Role: lead
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Role: lead
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Role: lead
Metformin for Rising PSA Remote Trial
Role: lead
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Role: lead
All 12 trials loaded